FDA Approves GSK’s Hibsago, the First ‘Functional Cure’ for Chronic Hepatitis B

The United States has approved the first medicine that can lift a meaningful share of people with chronic hepatitis B out of lifelong drug treatment, a milestone that hepatologists have chased for decades. The Food and Drug Administration said on Tuesday that it had cleared Hibsago — chemically known as bepirovirsen, from British drugmaker GSK — for adults with chronic hepatitis B infection, offering, for the first time, a realistic prospect of what doctors call a “functional cure” after a six-month course of injections.

Bepirovirsen is the first antisense oligonucleotide approved for chronic hepatitis B in the United States, according to the FDA, and it carries both of the agency’s innovation flags — priority review and Breakthrough Therapy designation — which are reserved for medicines judged to represent a significant improvement over existing options. In the pooled phase III B-WELL trials, six months of bepirovirsen produced a functional cure rate of 19 per cent — 233 of 1,220 patients — compared with none of the 614 patients given a placebo, GSK announced on Tuesday.

The approval covers adult patients without cirrhosis who have already been taking nucleos(t)ide analogue therapy for at least six months, whose hepatitis B virus DNA is suppressed, and whose surface antigen levels are at or below 3,000 IU per millilitre as measured by an FDA-authorised test. Functional cure, in the definition used by the trials, means that both HBV DNA and the surface antigen — HBsAg — become undetectable and stay undetectable for at least 24 weeks after all treatment has been stopped, a state that indicates the disease is under the immune system’s own control without medication.

That result stands against a bleak standard-of-care benchmark. Patients on today’s standard antiviral regimens typically see a functional cure rate of less than 1 per cent after a full year of treatment, according to GSK, and many remain on pills indefinitely while still facing the risk of liver damage. “Despite current therapies, many people living with chronic hepatitis B remain on treatment indefinitely and continue to face the risk of serious liver complications,” said Tony Wood, GSK’s chief scientific officer. “For the first time, with Hibsago, US patients have the potential to achieve functional cure after a six-month treatment course, with the added convenience of the option of self-administration after the first dose.”

The drug is given as a subcutaneous injection over up to 24 weeks alongside the patient’s existing antiviral therapy, which continues for at least another 24 weeks after the final bepirovirsen injection. An exploratory analysis from the trials showed bepirovirsen pushed HBsAg down to 100 IU per millilitre or lower in 49 per cent of participants overall, and in 62 per cent of those in the lower-antigen subgroup, by the week-72 visit — a low surface-antigen level that medical literature has linked to stronger immune control and better outcomes.

Norah Terrault, chief of gastroenterology and hepatology at USC’s Keck Medical Center, called the decision the beginning of a new era in the management of chronic hepatitis B, saying bepirovirsen gives patients “the potential to achieve functional cure after a short period of treatment, a long-standing goal for patients and physicians alike.” The approval was greeted with similar language by patient advocates: “Today marks significant progress towards our aim of transforming the way CHB is managed,” said Chari Cohen, president of the Hepatitis B Foundation, noting that chronic hepatitis B accounts for roughly 56 per cent of all global liver cancer cases.

The burden behind the approval

Chronic hepatitis B is one of the most entrenched infectious diseases on the planet. It develops when the immune system fails to clear the hepatitis B virus, producing a long-lasting infection that, according to the World Health Organization, affects more than 240 million people worldwide and causes about 1.1 million deaths a year. It is the leading cause of liver cancer cases globally. In the United States alone, roughly 1.7 million people live with chronic hepatitis B, according to modelling published in the Journal of Viral Hepatitis this year and cited by GSK.

The paradox of the disease is that a safe, effective preventive vaccine has existed for decades, yet the virus continues to kill at scale. Most of the world’s chronic infections were acquired in childhood, often at birth from an infected mother, in parts of Asia and sub-Saharan Africa where vaccination programmes arrived late or unevenly. By the time such patients reach adulthood and are diagnosed, antivirals can suppress the virus — but suppression is not elimination. The virus’s genetic blueprint persists inside liver cells in a resilient form, and the immune system, long exhausted by years of exposure, does not finish the job. Stopping pills typically brings the virus back.

That is the clinical ground bepirovirsen attacks. As an antisense oligonucleotide — a short, synthetic strand designed to recognise and block the virus’s RNA — it shuts down production of the viral genetic components and proteins that sustain chronic infection, lowering surface antigen levels in the blood and, according to GSK, potentially stimulating the immune system to regain control of the disease. The medicine was licensed from Ionis Pharmaceuticals, the antisense pioneer, and developed jointly with the company.

A first for the platform, not just the disease

The FDA’s decision is notable well beyond hepatitis B because it validates antisense chemistry as a therapeutic platform in infectious disease. Antisense oligonucleotides have been in clinical use for years in rare and neurological conditions, but Tuesday’s approval is the first time the approach has been authorised against a chronic viral infection of this scale — a disease measured in hundreds of millions of patients rather than thousands.

Regulators have queued up behind the science. Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address unmet need, according to GSK, with Breakthrough Designation and priority review from the FDA, Breakthrough Therapy and Priority Review status in China, and SENKU designation in Japan — a fast-track channel for innovative medicines. The drug is already approved in Japan as well as the United States, and GSK says it is advancing submissions across multiple other geographies, with key regulatory decisions expected in the coming months. The phase III results behind the approval were published in the New England Journal of Medicine in June (2026;394(24):2395-2406).

On safety, the trials showed what GSK described as an acceptable safety and tolerability profile, consistent with earlier studies of the drug. The three most frequently observed adverse events were redness at the injection site, local pain, and a temporary rise in a liver enzyme’s blood level — a side-effect profile that, while not trivial, is a long way from the toxicity that once defined antiviral medicine.

Analysis: Why It Matters

1. “Functional cure” is a promise worth parsing carefully

The headline phrase of Tuesday’s approval deserves careful unpacking, because the difference between a functional cure and a true cure is medically real. In a functional cure, the immune system keeps the virus suppressed without drugs — but fragments of the viral blueprint persist inside liver cells, and relapses, though uncommon in the trials so far, remain theoretically possible. Doctors emphasise that a functionally cured patient still needs monitoring. The distinction matters for how patients understand their prospects: this is not the same as the near-total viral eradication achieved by modern hepatitis C drugs. But for a disease where the realistic alternative has been daily pills for life, the option to stop treatment while the immune system holds the line is a genuine therapeutic revolution — and the 19 per cent versus near-zero comparison is the honest measure of it.

2. The antigen threshold is the new clinical gatekeeper

One of the most clinically consequential details in the approval is its eligibility rule: patients must have surface antigen levels at or below 3,000 IU per millilitre, measured by an FDA-authorised test. That single number effectively splits the patient population. In the trials’ key secondary analysis, patients at or below 1,000 IU per millilitre — a group GSK says represents roughly 45 per cent of diagnosed chronic hepatitis B cases globally — reached a functional cure rate of 26 per cent, with 200 of 768 patients achieving it versus none on placebo. The message to clinicians is clear: quantitative surface-antigen testing, not just viral-load testing, will now decide who gets offered this drug. That creates a new diagnostic dependency in the treatment pathway, and the availability of a recently FDA-authorised quantitative test will determine how quickly the eligible population can actually be found.

3. Antisense medicine has arrived in the major leagues

Tuesday’s approval is arguably as significant for the antisense field as for hepatitis B. Antisense oligonucleotides have spent decades as a platform of brilliant science and modest commercial reach, confined largely to rare diseases. Bepirovirsen’s journey — from Ionis’s chemistry to a GSK-scale development programme to approval against a disease that kills a million people a year — shows the technology can now aim at the largest infectious-disease targets. That validation is likely to redirect investment: every major antisense and RNA-interference programme watching this outcome now has a proof of concept that viral proteins, not just human genetic defects, are druggable through the platform. Competitors will be racing to improve on 19 per cent.

4. The real test is geography, not science

The approval’s most sobering limitation is geography. Chronic hepatitis B is overwhelmingly a disease of Asia and sub-Saharan Africa, where screening infrastructure is thin and most patients are diagnosed late or never. The United States — where roughly 1.7 million people carry the virus — is a small fraction of the global burden, and the economics of an injectable specialty drug licensed in the US and Japan will be watched closely by health systems in the countries that need it most. GSK says regulatory submissions are advancing in multiple geographies, with decisions due in the coming months, and China has already granted the drug breakthrough status — a signal that the world’s largest hepatitis B market is in play. Whether the medicine reaches the patients bearing most of the burden will depend on pricing, manufacturing scale, and the willingness of global procurement systems to treat a functional cure as worth paying for.

5. The hepatitis C playbook — and its limits

Hepatology has seen a cure story before. The direct-acting antivirals that transformed hepatitis C in the 2010s taught the field that a genuine cure reshapes everything — screening programmes expand because there is something to offer, treatment targets become elimination targets, and the disease’s fatalism lifts. Hepatitis B is not there yet: 19 per cent is a beginning, not an ending, and the virus’s persistence inside liver cells makes true eradication a harder scientific problem than hepatitis C ever was. But the directional signal is the same. Functional cure reframes chronic hepatitis B from a life sentence to a condition with a potential exit — and that reframing changes how patients, doctors and public-health agencies behave, even before the second generation of drugs arrives.

What to Watch Next

1. China and other regulatory decisions. GSK says submissions are under way in multiple geographies with key decisions expected in the coming months. China — with breakthrough and priority review status already granted — and European regulators will be the next major tests of the drug’s global footprint.
2. US pricing and payer coverage. The approval establishes eligibility through quantitative antigen testing; the commercial question now is what GSK charges and how insurers and Medicaid handle a six-month injectable course aimed at a population many of whom are uninsured or under-insured. Watch for the launch price and any patient-assistance commitments.
3. Diagnostic rollout. Because the indication hinges on an FDA-authorised quantitative HBsAg test at the 3,000 IU/ml threshold, clinics’ ability to identify eligible patients will gate uptake. Test adoption across community hepatology practices is the rate-limiting step most analysts will track.
4. Durability of response. Functional cure in the trials was measured six months after all therapies stopped. Longer-term follow-up — whether immune control holds for years, and what fraction relapse — will determine how confidently doctors can tell patients the virus is finished.
5. Next-generation combinations. Bepirovirsen’s 19 per cent sets a benchmark that combination regimens — antisense plus immune modulators, therapeutic vaccines, or capsid inhibitors in development across the industry — will aim to beat. Expect trial readouts pairing bepirovirsen-style RNA blockade with immune stimulation to define the next wave.

Sources

• GSK press release: Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)
• Reuters Health News Summary: US FDA approves GSK’s hepatitis B drug (via Devdiscourse)
• Healio: Hibsago scores FDA approval as first antisense therapy for chronic hepatitis B
• WHO Global Hepatitis Report 2026 (cited in GSK release)